Search

The article discusses the debate regarding the benefits of the prostate-specific antigen (PSA) test, which is a routine blood test that is used to screen for prostate cancer. According to the U.S. Preventive Services Task Force, little of no long-term benefits are derived from the test and may do more harm than good. Topics include controversies about PSA tests resulting from flawed screening methods and treatments, side effects of prostate cancer treatment, such as impotence, and the growing body of evidence against PSA screening that suggests screening guidelines need to be updated. INSET: Disappointing Data.

The article acknowledges U.S. immunologist James Allison for his work in the field of cancer-related research and development. Topics discussed include his recognition with the Nobel Prize in Physiology or Medicine for his pioneering work in cancer research, the role of his family's tragic cancer history and his plan to develop an immune-based therapy for the treatment of prostate cancer.

Examines treatment options for prostate cancer detected at an early stage. Details on the prostate specific antigen (PSA) test, a blood test that can find cancer at earlier stages than was previously possible; Methods used to fight prostate cancer, including the removal of the prostate, standard radiation and implantation of radioactive material into the prostate; Likelihood of men to have prostate cancer. INSETS: Milken accelerates cancer research, by Katy Kelly;Greens (and reds) may cut your risk, by Rachel K. Sobel.

Despite advanced efforts in early diagnosis, aggressive surgical treatment, and use of targeted chemotherapies, the prognosis for many cancers is still dismal. This emphasizes the necessity to develop new strategies for understanding tumor growth and metastasis. Here we use a systems approach that combines mathematical modeling and numerical simulation to develop a predictive computational model for prostate cancer and its subversion of the bone microenvironment. This model simulates metastatic prostate cancer evolution, progressing from normal bone and hormone levels to quantifiable diseased states. The simulations clearly demonstrate phenomena similar to those found clinically in prostate cancer patients. In addition, the major prediction of this model is the existence of low and high osteogenic states that are markedly different from one another. The existence and potential realization of these steady states appear to be mediated by the Wnt signaling pathway and by the effects of PSA on TGF- β , which encourages the bone microenvironment to evolve. The model is used to explore several potential therapeutic strategies, with some potential drug targets showing more promise than others: in particular, completely blocking Wnt and greatly increasing DKK-1 had significant positive effects, while blocking RANKL did not improve the outcome. [ABSTRACT FROM AUTHOR]

The article reports on the development in the treatment of cancer with the approach created by a team of oncologists at the Francis Crick Institute in London, England who used game theory in the treatment of men with advanced prostate cancer. It mentions that the team behind the method act as predators and the cancer cells are prey in an objective to kill the latter or to at least keep it in check.

Details the progress made in the detection and treatment of prostate cancer, which will strike one in eleven men and is the third leading cause of cancer deaths in men. INSET: Two prostate solutions (surgical treatment); Advancing the steps.

The article discusses the importance of prostate cancer diagnosis and treatment. Topics include the psychological effect of cancer to patients, the importance of collaboration between patients and doctors in providing treatment options to cure cancer, and the impact of advances in technology to accelerate the healing of patients from cancer. Also presented are the various cancer treatments which include hormonal therapy for advance prostate cancer cases, radical surgery, and radiation therapy.

A personal narrative is presented which explores the author's experience of fighting against prostate cancer and how his wife treated the disease by focusing on plant-based diet.

The article explores the potential of immunohistochemistry (IHC) for companion diagnostics. It presents challenges in reaching its full potential which include the lack of standardization and reproducibility for treating cancers like melanoma, non-small cell lung cancer, and prostate cancer. It also recommends changing the immunostain process, changing the antibody, and changing the detection system.

The article discusses views of pathologists on questions about active surveillance (AS) as treatment strategy for prostate cancer (PCA) patients. Topics include Dr. M. Elizabeth Hammond cited prostate needle biopsy while Dr. Jonathan I. Epstein discussed the Gleason score and AS also called watchful waiting connoting inaction. Also mentioned are Dr. John Gore discussing the patient prostate cancer tissue as to Genome Prostate Score, Prostate Specific Antigen (PSA) and urinary PCA gene3 (PCA3).

The article reports on the advances in prostate cancer treatment that ensure men to continue enjoying active lives during their treatment. According to Juravinski Cancer Centre's Doctor Sebastien Hotte, there is an increase in cancer treatment options. Also cited are the new treatments like triple therapy for metastatic castrate-sensitive prostate cancer (mCSPC), and the cancer type non-metastatic castrate-resistant prostate cancer (nmCRPC).

The article provides information on the updated guidelines for prostate cancer issued by the U.S. National Comprehensive Cancer Network (NCCN). It states that the process of prostate cancer detection is changing, and surveillance rather than treatment is offered to patients with lower-risk disease. Topics discussed include disease free survival of cancer patients, prostate-specific antigen (PSA), and medical screening.

The article provides information on clinical studies conducted to study the role of Apalutamide and Enzalutamide in delaying metastasis of prostate cancer for two years. Topics discussed include ongoing androgen deprivation therapy (ADT) and response to conventional hormonal therapy; quality of life; and prostate specific antigen (PSA).

The article talks about andropause, the condition among elderly men above 40 when their serum testosterone falls below normal. Topics include the effects of testosterone in young men from building muscles and strong bones to boosted energy levels and risky behavior, the necessary issues physicians will have to deal with in aging male patients such as the criteria, prescription, and the risks in testosterone replacement therapy, common symptoms of hypogonadism ad andropause, and prostate cancer.

The article reports on active surveillance on the management of prostate cancer in men in the U.S. It mentions University of Utah School of Medicine pathology professor M. Elizabeth H. Hammond who pointed out the perception patients towards pathologists and their lack of involvement in treating them. An overview of the perspective of Mahul Amin of Cedars-Sinai Medical Center on the issue is also presented.

The article offers brief information on several natural health products including the Prostate 40+ product for prostate cancer from Ovos, the Power Play Sport sports drink from Innotech Nutrition and the Ear Tone product for tinnitus from New Nordic.

The article explores the rise of using robotic surgery, which as of 2014 performs 83 percent of about 60,000 surgeries yearly. Topics discussed include the benefits offered by robotics surgery to patients postoperatively, the concerns raised by Johns Hopkins University and others on negative consequences arising from using robotics during surgical procedure and the influence of the doctor operating the robot on the quality of the surgery.

The article discusses the development of high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer and brain surgery by the engineer Morry Blumenfeld. Topics include detail's on Morry's role running the advanced development at GE Medical, details on the technology behind the treatment, and the problem of spreading the word about the treatment in the medical industry.

The article offers information on the use of several new techniques and technologies to stay healthier and heal faster. It discusses 20 advanced technologies used in the hospitals of Minnesota for the treatment of blood pressure, stoke and prostate cancer. It informs that the software applications are used for scheduling appointments to dispensing medical advice and learn more about medical conditions.

The article presents a case study of a 76-year-old man who was admitted to the Nuclear Medicine department at Sir Charles Gairdner Hospital for a bone scan in April 2013. It notes that the patient was an in-patient at Sir Charles Gairdner Hospital and had been in hospital for four days, and had a history of locally advanced adenocarcinoma of the prostate that required an assessment of the disease extent prior to therapy.

The article offers information on the ongoing phase two clinical trial for Exelixis Inc.'s new drug cabozantinib to evaluate the effect of the drug in treatment of metastatic castration-resistant prostate cancer (CRPC) and bone metastases in men. Clinical studies demonstrate positive effect of cabozantinib on bone related pain and narcotic use.

The article informs that 600 patients have been enrolled for the phase three clinical trials conducted by Active Biotech AB and the company Ipsen for evaluating the efficacy of the drug, tasquinimod in treatment of patients suffering with metastatic castrate resistant prostate cancer (CRPC). The clinical study on tasquinimod aims to demonstrate radiological progression free survival (PFS) of the drug in prechemotherapy setting.

The article offers information on the data presented by Dendreon Corp. at the American Urological Association (AUA) Annual Meeting being held in Atlanta, Georgia from May 19-23, 2012 to demonstrate the results of phase three clinical trials on Sipuleucel-T, Provenge which is used in treatment of metastatic castrate resistant prostate cancer. According to the study, positive results were seen with the use of Provenge.

The article offers information on a clinical trial data to be presented at annual meeting of the American Society of Clinical Oncology that will be held in Chicago from June 1-5, 2012 by Dendreon Corp. for showing the efficacy of a drug Sipuleucel-T in prostate cancer treatment. Several presentations depicting overall survival benefit, evaluation of immune activation and relationship between eosinophil count and drug will be presented by the company.

The article offers information on the expansion of global research enterprise by Prostate Cancer Foundation (PCF) for expanding its global knowledge exchange in 2012 for prostate cancer research, PCF provides funding to innovative minds in the field of prostate cancer research. The new 2012 PCF Young Investigator Award was given to 15 participants among 148 applicants who applied for 2012 PCF Young Investigator funding.

The article presents information on an announcement made by Astellas Pharma Europe Ltd. regarding the data exhibited at the European Association of Urology (EAU) congress in Paris, France, according to which drug MDV3100 extended life by five months in comparison with placebo in men with advanced prostate cancer. MDV3100 is developed by Astellas Pharma Inc. in collaboration with Medivation Inc.

The article presents information on the exploration of a drug delivery system for effective delivery of chemotherapeutic drugs to the prostate cancer cells. The study is a joint effort of the researchers from Massachusetts Institute of Technology, Cambridge, Massachusetts and Massachusetts General Hospital, Boston, Massachusetts and Brigham and Women's Hospital, Boston, Massachusetts.

Several letters to the editor are presented in response to articles in previous issues including one in the September 21, 2013 issue about a study on men with prostate cancer, one from the September 14, 2013 issue on Australian prime minister Tony Abbott, and one in the August 10, 2013 issue on artificial intelligence.

The article reports on the move of South Francisco, California-based Exelixis Inc. to provide information on the interim data regarding the use of narcotic analgesic with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases. It highlights the important role of cabozantinib in controlling the pain associated to bone metastases in men with progressive CPRC. Furthermore, Dr. Howard Scher will present the data at an international meeting on November 14, 2011.

The article presents a study, conducted by researchers at the Centenary Institute in Sydney, New South Wales, on prostate cancer in 2011. Researchers have found a potential future treatment for prostate cancer by starving the tumour cells of a significant nutrient they require to quickly grow. The work of researchers, having human cells in the laboratory, shows targets for drugs that slow the progress of late and early stage prostate cancer.

The article discusses the cost associated with the treatment of prostate cancer (PCa) in the U.S. It states that the disease is considered as the most prevalent cancer in the males and the most frequently diagnosed among all types of the condition. It provides an overview of the guidelines set by the National Comprehensive Cancer Network in treating the disease and recommends further research to provide treatment options in an era of increased of economic scrutiny. INSET: Case Study: The Need for Cost-Effective Treatment.

The article offers information on various drugs used for the treatment of prostrate cancer. One of these drugs is Eligard manufactured by Sanofi Aventis SA which serves as a palliative treatment of advanced prostate cancer. Another is Estrace from Warner Chilcott used as a palliative treatment for androgen-dependent advanced prostate cancer. Meanwhile, delestrogen manufactured by JHP Pharmaceuticals LLP is also a palliative treatment for advanced androgen-dependent carcinoma of the prostate.

The article reports on the move of Exelixis Inc. to initiate the '306 trial, the first phase 3 pivotal trial of cabozantinib in patients with metastatic castration-resistant prostate cancer (CRPC) in the U.S. It mentions that the Food and Drug Administration (FDA) asserts that the trial can be conducted without a special protocol assessment (SPA). It states that it is designed to enroll 246 patients with CRPC who are suffering severe bone pain despite optimized narcotic medication.

The article discusses a step-by-step approach for intermittent androgen deprivation therapy (ADT) in prostate cancer. It mentions the primary goal of ADT which is the pharmacologic suppression of gonadal testosterone production with medical castration and is achieved with either luteinizing hormone-releasing hormone (LHRH) analogues or antagonists. It concludes that the use of intermittent ADT does not appear to negatively affect overall survival and improved quality of life. INSET: Case Study: On- and off-treatment intervals.

AUSTRALIA - Asian Mushrooms Could Help Fight Prostate Cancer AUSTRALIA - New Lung Cancer Treatment Discovered AUSTRALIA - Gene Behind Rare Brain Disorder Identified CHINA - China Bans Controversial Drug for Kids Below 12 INDIA - Ovarian Cancer Treated with Immunotherapy INDIA - Gene Card Tells What Drugs to Avoid INDIA - IISc, Deakin Join Hands to Fight Cancer with Nanotechnology INDIA - Indian Govt to Introduce First Five-in-One Vaccine SINGAPORE - New Test for Pain Tolerence SINGAPORE - NUS Best University for Medicine in Asia OTHER REGIONS - Implant Breakthrough Helps Paraplegic Man Stand Unaided OTHER REGIONS - Scientists Discover Protein that can Halt Spread of Breast Cancer [ABSTRACT FROM AUTHOR]

The article focuses on the May 19, 2011 announcement by Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals Inc. on the custirsen data presentation at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois on June 3-7, 2011. It discusses preclinical studies findings of custirsen with MDV3100 in castrate resistant prostate cancer (CRPC). Yitzhak Peterburg of Teva says that Teva and OncoGenex are encouraged by the custirsen findings benefits.

The article focuses on the results of two clinical studies of Calypso Medical Technologies Inc. concerning the application of calypso system in five-day stereotactic body radiotherapy (SRBT) for prostate cancer treatment. Calypso chief medical officer Kenneth Russell says that radiation delivery was safeguarded using the real-time tracking technology. The result of the other study shows the favorable toxicity outcomes and quality of life on the use of technology.

The article reports on U.S. Food and Drug Administration's (FDA) approval of ZYTIGA (abiraterone acetate) from Centocor Ortho Biotech Inc. for treating men with metastatic prostate cancer after receiving prior chemotherapy containing docetaxel. It notes that ZYTIGA is an oral, once-daily medication in combination with prednisone for treating the metastatic disease. Moreover, the role of androgens in fueling the growth of the tumor is discussed.

The article offers information on the practice of oncology, highlighting several pharmaceutical products for treating diseases. Diseases being presented include prostate cancer and bladder cancer. The application of hormonal therapy in the treatment of androgen-dependent prostate cancer to counteract the effects of testosterone is discussed.

The article discusses aspects on the treatment of prostate cancer. According to Durado Brooks, director of prostate and colorectal cancers for the Atlanta, Georgia based American Cancer Society, prostate cancer has been the most common cancer among American men and the most common cause of cancer deaths in men. A revised screening guideline by the American Cancer Society has required men at the age of 40 and 35 for African American to undergo screening and to understand the risks involved.

The article presents a case study of 62-year-old man who diagnosed and treated for his metastatic prostate cancer using 68Gallium-PSMA.

The article offers information on several drugs along with their indications and contraindications for the treatment of prostate cancer. Casodex from AstraZeneca Pharmaceuticals LP is being used to treat stage D2 metastatic prostate carcinoma. Pfizer Inc.'s Emcyt is used for the treatment for metastatic, progressive prostate cancer. Firmagon from Ferring Pharmaceuticals Inc. is used to treat advanced prostate cancer and is not recommended for children.

The article focuses on the use of high dose rate (HDR) brachytherapy for the treatment of prostate cancer developed at Bristol Haematology and Oncology Center in Great Britain. It details the procedure for the brachytherapy stressing its involvement of a number of thin hollow catheters into the prostate gland through the perineum. It notes the submission of the patient to the lithotomy position and catheterized wherein the rectal ultrasound probe is attached to a stepper unit and images of the prostate. The typical side effects of the HDR brachytherapy which include inflammation of urethra causing frequency and pain, urinary incontinence, and erectile dysfunction are cited.

The article offers information on the different drugs for neoplasm in the U.S. It emphasizes the need for full familiarization with cancer chemotherapy before using any of the preparations. The drugs listed here include Aromasin for breast cancer, Casodex for prostate carcinoma and Cyclophosphamide for multiple myeloma.